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ABSTRACT
The identification of multilocus imprinting disturbances (MLID) appears fundamental to uncover
molecular pathways underlying imprinting disorders (IDs) and to complete clinical diagnosis of
patients. However, MLID genetic associated mechanisms remain largely unknown. To characterize
MLID in Beckwith-Wiedemann (BWS) and Silver-Russell (SRS) syndromes, we profiled by
MassARRAY the methylation of 12 imprinted differentially methylated regions (iDMRs) in 21
BWS and 7 SRS patients with chromosome 11p15.5 epimutations. MLID was identified in 50% of
BWS and 29% of SRS patients as a maternal hypomethylation syndrome. By next-generation
sequencing, we searched for putative MLID-causative mutations in genes involved in methylation
establishment/maintenance and found two novel missense mutations possibly causative of MLID:
one in NLRP2, affecting ADP binding and protein activity, and one in ZFP42, likely leading to loss
of DNA binding specificity. Both variants were paternally inherited. In silico protein modelling
allowed to define the functional effect of these mutations. We found that MLID is very frequent in
BWS/SRS. In addition, since MLID-BWS patients in our cohort show a peculiar pattern of BWS-
associated clinical signs, MLID test could be important for a comprehensive clinical assessment.
Finally, we highlighted the possible involvement of ZFP42 variants in MLID development and
confirmed NLRP2 as causative locus in BWS-MLID.
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Introduction
Beckwith-Wiedemann (BWS, OMIM #130650) and
Silver-Russell (SRS, OMIM #180860) syndromes are
paired imprinting disorders (IDs) caused by opposite
molecular defects at the 11p15.5 chromosomal
region, which harbors two imprinted domains,
IGF2/H19 and CDKN1C/KCNQ1OT1, regulated by
different imprinting control regions, ICR1 and ICR2,
respectively [1,2]. Loss of methylation (LOM) at
ICR1 accounts for over 50% of SRS cases, while
gain of methylation (GOM) at ICR1 and LOM at
ICR2 trigger BWS in approximately 10% and 60% of
cases, respectively. In addition, maternal uniparental
disomy of chromosome 7 (mUPD7) and paternal
UPD of 11p15.5 are present in 7–10% of SRS and
20% of BWS, respectively [3–5].
The two syndromes exhibit opposite phenotypes.
BWS is an overgrowth condition characterized by
macrosomia, macroglossia, hemihyperplasia, viscer-
omegaly with consequent abdominal wall defects,
and increased risk of embryonal tumors [1].
Conversely, growth restriction, relative macroce-
phaly, peculiar small and triangular face, the fifth
finger clinodactyly, and hemihypoplasia are charac-
teristic of SRS [2].
The phenotypic heterogeneity of BWS/SRS and
the presence of clinical features overlapping with
CONTACT L. Fontana laura.fontana@unimi.it Laboratory of Molecular Pathology, Department of Pathophysiology and Transplantation, Università
degli Studi di Milano, Milano, Italy
*The authors equally contributed to the paper
Supplemental data for this article can be accessed here.
EPIGENETICS
2018, VOL. 13, NO. 9, 897–909
https://doi.org/10.1080/15592294.2018.1514230
© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-
nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built
upon in any way.
other IDs [6–8], have prompted the investigation
of methylation defects at additional imprinted
genes in patients with epimutations at the dis-
ease-specific locus, leading to the identification of
a subset of patients with aberrant methylation
affecting other imprinted differentially methylated
regions (iDMRs), a condition described as multi-
locus imprinting disturbance (MLID). MLID has
been identified in BWS patients at frequencies of
up to 30% in patients with LOM at ICR2 [6–14],
while it is very rare among cases with GOM at
ICR1 [15]. Some BWS patients with MLID show
LOM or GOM at both maternal and paternal
DMRs [8,15], while others have a hypomethylation
syndrome restricted to maternally imprinted genes
[16–18]. MLID has less frequently been described
in patients with SRS (~ 15%) [8].
The phenotypic consequences of MLID in
BWS and SRS patients are disputed, since not all
patients with MLID show peculiar phenotypic
features, probably as a consequence of the (epi)
dominance of one locus above the others [19] or
as a result of mosaicism. However, some excep-
tions have been reported. Specifically, birth
weight is usually lower in patients with MLID
than in those with mono-locus BWS, and macro-
somia is less frequent; patients with MLID can
present features not related to BWS (speech retar-
dation, apnea, and feeding difficulties) [7]. SRS
patients with MLID more frequently exhibit
growth delay and additional congenital abnorm-
alities [6]. MLID-associated clinical signs may
also only manifest as patients grow up; therefore,
MLID analysis, after molecular confirmation of a
specific ID, may guide a patient-tailored follow-
up to monitor for subclinical signs before their
manifestation [17,20].
The etiology of MLID remains to be elucidated,
as do the mechanisms underlying the co-regulation
of imprinting marks across the genome. Despite the
identification of MLID causative mutations in
members of the NLRP and zinc-finger protein
families in few BWS/SRS patients [10,21,22], the
role of these proteins in the imprinting process
and the pattern of inheritance remain to be fully
elucidated. A role for NLRP mutations in MLID
was suggested based on the observation of shared
hypomethylated loci between MLID and hydatiform
mole [23]. In particular, NLRP7 mutations have
been associated with the most severe form of
MLID, the biparental hydatiform mole [24]. In
addition, maternally-derived mutations of NLRP2
and NLRP5 genes, already associated to molar preg-
nancies, have been identified in BWS/SRS patients
with MLID; however, the type of epimutations
(hypo/hypermethylation), the extent of the methy-
lation defect, and the number/type of affected
iDMRs in MLID suggest a different mechanism of
pathogenicity compared to molar pregnancies
[21,22]. Indeed, in NLRP mutated MLID cases, the
affected iDMRs appear to vary, and intermediate
levels of LOM suggest a post-zygotic effect. In addi-
tion, both homozygous and heterozygous causative
mutations in the NLRP genes have been reported in
BWS patients, suggesting a variable pattern of
inheritance [8,21,22,25]. Furthermore, incomplete
penetrance may account for the variability observed
among patients with the same pathogenic muta-
tions [21].
Mutations in genes encoding members of the
zinc-finger protein family have been considered
good candidates as causative defects of MLID,
given the well-established role of ZFP57 mutation
in patients with transient neonatal diabetes melli-
tus and MLID [26,27]. However, no mutations
have been found to date in other members of the
protein family in MLID patients.
Here, we report the methylation profiling of 12
iDMRs investigated simultaneously by MALDI-
TOF Mass Spectrometry (MassARRAY) in 21
BWS and 7 SRS patients presenting with chromo-
some 11p15.5 epimutations. This approach allowed
the identification of MLID in approximately 50%
and 29% of patients with BWS and SRS, respec-
tively. Targeted next-generation sequencing (NGS)
of a panel of genes involved in methylation estab-
lishment/maintenance highlighted two novel mis-
sense mutations possibly associated with MLID.
Results
Multi-locus methylation disturbances in patients
with BWS and SRS
The MassARRAY methylation assays were opti-
mized using 50 blood age-matched controls and
20 amniotic fluids (AF) to define the physiological
methylation ranges at each iDMR (Figure 1 and
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Supplementary Figure S1). Methylation analysis of
the 12 iDMRs allowed the identification of MLID
in 10 of 21 cases with BWS (50%) and 2 of 7 with
SRS (29%) (Figure 1). Notably, among the BWS
patients, MLID was detected only in those with
ICR2 LOM (10 of 17 cases, 59%).
MLID involved only maternally imprinted loci in
patients with both BWS and SRS, although the
affected iDMRs and the degree of the methylation
defect varied among cases (Figure 1). One BWS case
(BWS-3) showed hypomethylation at only one
additional iDMR, while all other cases exhibited
LOM at two or more iDMRs (Figure 1). Case
BWS-7 exhibited the most extensive MLID, with
methylation defects at five additional iDMRs.
DIRAS3-CG1, FAM50B, MEST, and GNASXL
iDMRs were the most frequently involved loci:
DIRAS3-CG1 LOM was observed in seven cases
(25%), while FAM50B, MEST, and GNASXL
LOM were detected in five samples (18%).
Among the analyzed iDMRs, only PLAGL1 and
MEG3 did not show aberrant methylation in any
iDMR ARH-CG1 ARH-CG2 FAM50B PLAGL1 PEG10 MEST DLK1 MEG3 GNASA/B GNASXL ICR1 ICR2 
Locus 1p31.3 1p31.3 6q25.2 6q24.2 7q21.3 7q32.2 14q32.2 14q32.2 20q13.32 20q13.32 11p15.5 11p15.5 
Imprinting M M M M M M M P M M P M 
BWS-1 54 55 43 51 50 56 58 43 36 46 50 17 
BWS-2 49 36 35 49 45 31 58 45 47 42 51 5 
BWS-3 51 50 46 55 48 51 57 48 34 39 49 18 
BWS-4 N.A. 49 20 N.A. N.A. 62 55 45 35 21 48 21 
BWS-5 25 58 13 51 46 43 52 45 39 30 48 15 
AF CTRLs 33-63 50-74 38-46 42-62 44-60 43-61 51-61 42-51 33-48 37-53 44-50 35-53 
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BWS-6 47 51 39 56 47 51 56 43 42 38 53 10 
BWS-7 16 24 30 57 41 20 59 48 40 39 51 22 
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BWS-9 43 55 35 58 21 51 52 42 41 31 49 28 
BWS-10 60 53 43 55 50 56 56 44 39 40 47 31 
BWS-11 56 55 41 50 47 50 54 46 42 39 46 7 
BWS-12 47 54 38 47 48 50 56 47 41 42 48 30 
BWS-13 59 55 40 52 47 54 54 45 40 39 50 17 
BWS-14 29 55 42 57 41 52 53 46 41 34 47 13 
BWS-15 32 33 27 55 41 52 53 46 40 39 53 29 
BWS-16 39 53 43 57 45 30 59 47 42 41 51 22 
BWS-17 37 41 24 55 46 49 58 44 20 45 46 29 
BWS-18 59 52 41 57 48 47 60 42 40 39 54 41 
BWS-19 54 49 38 50 49 52 55 40 42 39 59 41 
BWS-20 45 56 46 54 56 55 52 45 48 55 60 45 
BWS-21 53 61 39 55 54 53 55 44 44 42 62 44 
SRS-1 55 56 42 52 46 57 54 45 39 39 35 37 
SRS-2 53 62 33 54 47 52 57 46 39 45 29 41 
SRS-3 48 52 38 50 45 53 57 45 41 38 27 5 
SRS-4 48 52 34 52 45 16 52 48 40 37 25 45 
SRS-5 46 49 36 54 47 46 54 46 41 41 35 43 
SRS-6 28 59 35 55 45 22 58 40 44 31 32 45 
SRS-7 54 62 41 57 49 52 60 42 40 40 36 42 
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Figure 1. Methylation analyses of 12 imprinted iDMRs by MassARRAY in patients with BWS and SRS with known epimutations at
ICR1 or ICR2. Cases with MLID are underlined. Aberrant methylation was defined as methylation values deviating +/- two standard
deviations from the mean value observed in amniotic fluid (AF) or blood control samples. Different shades of yellow indicate 5%
intervals of LOM (with light yellow corresponding to slight LOM and dark yellow corresponding to heavy LOM), while different
shades of blue represent 5% intervals of GOM (from light blue corresponding to slight GOM to dark blue indicating heavy GOM). The
last two columns contain ICR1/ICR2 methylation values determined by pyrosequencing, according to protocols previously described
[41]. *t-test ICR1 MassARRAY vs. ICR1 pyrosequencing: P = 0.2302. §t-test ICR2 MassARRAY vs. ICR2 pyrosequencing: P = 0.4391.
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BWS/SRS case. In addition, both cases with SRS
and MLID exhibited severe hypomethylation at
MEST (7q32), involved in maternal UPD(7q) in
SRS patients [28].
Finally, ICR1 (P = 0.2302) and ICR2 (P = 0.4391)
methylation results obtained by MassARRAY over-
lapped those obtained by Pyrosequencing for diag-
nostic purposes (Figure 1).
MLID putative causative mutations identified by
NGS
Targeted NGS analysis was performed for all BWS
and SRS cases with molecular evidence of MLID.
Genes included in the NGS panel (Supplementary
Table S1) were chosen among those involved in
the establishment and maintenance of parental
allele-specific DNA methylation during embryonic
development [29]. The use of a targeted gene panel
can be considered as a proof of concept for the
research of pathogenic variants of MLID. By NGS
analysis, we identified two likely pathogenetic
mutations. The first was a novel missense muta-
tion in the NLRP2 gene, c.656A> C (p.(K219T);
ENST00000339757.11), in patient BWS-15
(Figure 2(a)). The mutation was heterozygous,
inherited from the father and absent in a subse-
quent pregnancy of the family (healthy at birth)
(Figure 2(a)). The mutation was absent in 100
controls analyzed. The observed mutation falls in
NLRP2 exon 6, encoding the NOD nucleotide
binding domain crucial for protein activation by
oligomerization (Figure 2(b)) [30]. Moreover, the
affected amino acid is phylogenetically conserved,
suggesting a role in protein activity (Figure 2(c))
and the mutation was predicted to be pathogenic
using in silico tools (Figure 2(d)). The second
variant identified was a heterozygous SNP in the
ZFP42 gene (alias REX1, REX-1) in patient SRS-4,
c.640C>G (p.(P214A); ENST00000326866.4,
rs61748605) (Figure 3(a)), which was present in
both the Broad Institute ExAC Browser and the
1000 Genomes database, with minor allele fre-
quencies (MAF) of 0.004 and 0.005, respectively.
This variant was inherited from the father
(Figure 3(a)) and was not identified in controls.
It lies in the only coding exon and affects the first
linker domain between consecutive C2H2-
domains involved in DNA binding (Figure 3(b)).
The affected amino acid residue is phylogenetically
conserved (Figure 3(c)) and was predicted to be
damaging by in silico tools (Figure 2(d)).
Interestingly, the carrier fathers of both mutated
patients did not show multi-locus defects nor phe-
notypic alterations (data not shown).
NLRP2 and ZFP42 mutations affect protein
conformation and activity
The NLRP2 variant (c.656A>C) identified in patient
BWS-15 affects the NOD central domain, compris-
ing the nucleotide-binding domain (NBD), the heli-
cal domain (HD) and the winged-helix domain
(WHD). These subdomains contain characteristic
motifs (Walker A and B, sensor 1 and 2) involved
in ADP binding domain and ATP hydrolysis. The
K219 mutated residue is localized in the Walker A
motif. No differences in the protein secondary struc-
tures were predicted in silico (data not shown).
Comparison between wild type (wt) and mutated
(mut) NLRP2 molecular dynamics highlighted a sig-
nificantly different conformation of the NOD
domain. In the wtNLRP2, ADP makes hydrogen
bonds with specific residues of the NBD1 and
WHD subdomains of NOD (Figure 2(e)). These
interactions allow the subdomains of NOD to be
packed in a closed conformation. In the
mutNLRP2, ADP makes hydrogen bonds only with
residues of the NBD1 domain (Figure 2(e)).
According to literature data, the conformation of
the mutNLRP2, would facilitate conformational
changes in the WHD, leading to reduced ADP bind-
ing [30].
Significant differences in binding free energies
of ADP between wt and mutNLRP2 confirmed the
effect of the K219T mutation on ADP binding.
The mutNLRP2 showed a consistent decrease in
the binding energy compared to the wtNLRP2/
ADP complex (−103.5710 Kcal/mol for wtNLRP2
vs. −52.6973 Kcal/mol for mutNLRP2 – data not
shown). To obtain a detailed profile of the binding
process, the total binding free energy was further
decomposed to each residue (Supplementary
Figure S2). In the wtNLRP2, the K219 residue
appeared to significantly contribute to the binding
energy (with value of −60 kcal/mol), thus support-
ing its key role in ADP binding and subsequent
protein activation.
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The ZFP42 variant (c.640C>G) is localized in
the linker region between the first and second zinc
finger of the ZFP42 protein and is not predicted to
impact protein secondary structure (data not
shown). Molecular dynamics highlighted a greater
flexibility of the linker in the mutZFP42 compared
to the wtZFP42 (Figure 3(e)). Proline imposes a
conformational restriction on linker, that is lost
when it is substituted with alanine. This amino
acid change introduces conformational freedom
Figure 2. In silico analysis of the NLRP2 mutation. (a) Pedigree of the index case identified as heterozygous for a novel c.656A> C
mutation in the NLRP2 gene, as shown in electropherograms. The observed mutation was inherited from the father. (b) Schematic
representation of the NLRP2 gene and its encoded protein, indicating the position of the identified mutation. (c) Phylogenetic
conservation of the amino acid affected by the observed mutation. (d) In silico pathogenic prediction. (e) wt- and mutNLRP2
modelling. In wtNLRP2 ADP is bound to the NBD1 subdomain of NOD: R169 atoms form hydrogen bonds with the N1 and N6 atoms
of the adenine base, the T221 atoms form three hydrogen bonds with the α-phosphate group of ADP and the T220 G216 and K219
atoms form three hydrogen bonds with the b-phosphate groups of ADP. ADP also binds to the WHD subdomain of NOD by forming
three hydrogen bonds between the H503 residue and the α-phosphate group. In mutNLRP2, ADP makes hydrogen bonds only with
residues of the NBD1 subdomain: R169 atoms form hydrogen bonds with the N1 and N6 atoms of the adenine base, the G218, T221
and T220 atoms form four hydrogen bonds with the α-phosphate group, while the E136 atoms make four hydrogen bonds with the
ribose hydroxyl groups.
Symbols: * (asterisk) indicates a fully conserved residue; colon (:) indicates conservation between groups of strongly similar amino
acids; dot (.) indicates conservation between groups of weakly similar amino acids.
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in the linker, decreasing the probability of binding
to the target DNA.
Epigenotype-phenotype correlations
In our cohort of BWS cases, MLIDwasmore frequent
in females (P=0.03 Fisher’s exact test), with amale-to-
female ratio of 1:4 (Figure 4 and Supplementary
Figure S3); this finding is not ascribable to sex bias in
the original cohort, composed by 10 males and 11
females.
No significant differences between the clinical fea-
tures of patients with mono-locus and multi-locus
BWS were observed, as previously reported [19].
a
wt/c.640C>G wt/wt 
II-1 
wt/c.640C>G 
Exon 1 Exon 2 Exon 3 Exon 4 
CH CH CH CH 
188 212 
NH2 COOH 
217 239 245 269 275 299 
5’ 3’ 
p.(P214A) 
c.640C>G 
= non coding 
= coding 
CH: Cys-His domain 
I-1 I-2 
b 
Homo_sapiens          RKKPPINKEYDSLSAIACPQSGCTRKLRNRAALRKHLLIHGPRDHVCAECGKAFVESSKL
Mus_musculus          AEKPEGGVYCGVLSMLECPQAGCKKKLRDKTALRKHMLVHGPRRHVCAECGKAFTESSKL
Macaca_mulatta        RKKPPVSKEYDSLSAIACPQSGCSKKLRNTAALKKHLLTHGPRDHICAECGKAFVESSKL
Gorilla_gorilla       RKKPPINKEYDSLSAIACPQSGCTRKLRNRAALRKHLLIHGPRDHVCAECGKAFVESSKL
Equus_caballus        RKKPGKNQECDAPEKIVCPQSGCTKKLKNKASLRKHLLVHGPRDHVCAECGKAFNESTKL
Canis_familiaris      GKKPTKDKESEAPEKIVCPHSGCTKKLKSRASLRKHLLVHGPRDHAFESCGKRFIQSNNL
                       :**  .      . : **::**.:**:. ::*:**:* **** *   .*** * :*.:*
c 
Tool  Score Prediction 
Polyphen-2 0.995 Damaging 
Mutation Taster 0.977 Disease causing 
PROVEAN -7.993 Damaging 
SNAP2 28 Effect 
PANTHER 1368 Probably damaging 
MutPred 0.495 Probably damaging 
CADD score 24.1 Pathogenic 
d 
e 
Figure 3. In silico analysis of the ZFP42 mutation. (a) Pedigree of the index case identified as heterozygous for the reported c.640C>G
variant in the ZFP42 gene, as shown in electropherograms. The observed mutation was inherited from the father. (b) Schematic
representation of the ZFP42 gene and the encoded protein indicating the position of the identified mutation. (c) Phylogenetic
conservation of the amino acid affected by the observed mutation. (d) In silico prediction of pathogenicity. (e) wt and mutZFP42
modelling. Representative conformations of zinc finger motif conformations of the two most populated clusters (obtained from
clustering molecular dynamics trajectories) are shown in magenta and cyan cartoons. The side chains of the P214 and A214 residues
are represented by sticks.
Symbols: * (asterisk) indicates a fully conserved residue; colon (:) indicates conservation between groups of strongly similar amino
acids; dot (.) indicates conservation between groups of weakly similar amino acids.
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Nevertheless, it is intriguing that a number of clinical
features appeared to bemore frequent in patients with
MLID (Figure 4), such as facial nevus flammeus (5/6
MLID vs. 3/10 non-MLID), and, in contrast with
previous reports [7], macroglossia (6/6 MLID vs. 6/
10 non-MLID) and outer ears anomalies (3/6 MLID
vs. 1/10 non-MLID). Also, abdominal wall defects
were more frequent in both pre- and postnatal
BWS-MLID patients (8/10 MLID vs. 4/11 non-
MLID).
Differently from BWS cases, in which the diag-
nosis was clinically suspected, in both SRS-MLID
patients the clinical diagnosis was misleading
because of the presence of uncommon clinical
features (i.e., nevus flammeus, hypoglycemia and
abdominal wall defects, Figure 5). In these cases,
the molecular evaluation was resolving, showing
ICR1 hypomethylation in both patients, thus clas-
sified as SRS.
Discussion
Molecular characterization ofMLID is emerging to be
fundamental not only to better define the clinical
diagnosis of IDs but also to evidence common func-
tional networks at the basis of the genome-wide dereg-
ulation of imprinting. The frequency ofMLID appears
to vary depending on the sensitivity of the technology
used for analyses and the iDMRs investigated [6–
8,15,19]. In this study, we set up a panel of 12
Figure 4. Clinical features of pre- and postnatal BWS cases (Weksberg criteria). Cases with MLID are underlined. Empty circles
indicate prenatal signs. §No other phenotypic data available. a, Polyhydramnios; b, Myopia, lombo-sacral cutaneous spots; c, Frontal
angioma; d, Renal asymmetry, lypoma right leg. Abbreviations: TA, therapeutic abortion; B, born; IUFD, intrauterine fetal death; d,
days; m, months; y, years.
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iDMRs byMassARRAY technology and applied it to a
cohort of patients with BWS, presenting with primary
GOM at ICR1 or LOM at ICR2, and with SRS, show-
ing LOM at ICR1. We found a higher frequency of
MLID in both BWS (50%) and SRS (29%) patients,
compared with previous reports [6–8,15,19], probably
because we selected the iDMRs most frequently asso-
ciated with BWS/SRS. Our data confirm that the
iDMRs involved in both BWS- and SRS-MLID can
vary among patients, supporting that the defect is
non-recurrent. Nevertheless, we found that DIRAS3-
CG1, FAM50B, MEST, andGNASXL iDMRs were the
most frequently affected loci.
In our cohort, we only identified MLID in BWS
patients with ICR2 LOM, and hypomethylation was
found only at maternally iDMRs. This phenom-
enon, known as multiple maternal hypomethylation
syndrome, has previously been described for BWS
[7,16,17]. Only two studies reported on MLID as
GOM at paternally methylated iDMRs in BWS
patients [8,15]; however, also in these cases, MLID
was supposed to arise as a consequence of a methy-
lation defect of the maternal allele.
Considering the parental derivation and the
variable degree of LOM of the affected allele, sug-
gestive of mosaicism, in patients with BWS MLID
is likely due to post-zygotic loss of maintenance of
methylation at maternally imprinted alleles. This
hypothesis is also supported by the following evi-
dences: i) both BWS epimutations (ICR1 GOM or
ICR2 LOM) result from defective methylation of
the maternal allele, and ii) no [7,19], or very few
[15] cases with MLID have been identified among
ICR1 hypermethylated patients.
Regarding SRS, although our study included a
limited number of cases, the results indicate that
SRS-MLID is less frequent and involves fewer
iDMRs than BWS-MLID. Similar to BWS, SRS-
MLID can be defined as a hypomethylation syn-
drome; however, SRS-MLID patients did not exhi-
bit any correspondence between the affected allele
of the causative epimutation (paternal ICR1) and
the parental origin of the other iDMRs involved
(all maternal). This may be because of different
mechanisms underlying the MLID phenomenon
in patients with SRS. Also, in SRS, the methylation
impairment appears to be post-zygotic.
Interestingly, the only two SRS patients with
MLID shared severe hypomethylation at the MEST
gene.MEST hypomethylation in SRS-MLID has also
been reported by other authors [8,19,28,31] as a
distinct mechanism compared to mUPD(7), leading
to GOM at this iDMR [32]. In our cases, LOM at
MEST in SRS-MLID patients further sustains a key
role of this iDMR in SRS. Since both pathogenic
mutations and isolated epimutations at this iDMR
Figure 5. Clinical features of postnatal SRS patients (Netchine-Harbison criteria). Cases with MLID are underlined. a, Diastasis recti; b,
Fifth finger clinodactyly; c, Neonatal hypoglycemia, diastasis recti, facial nevus flammeus, neuromotor delay. Abbreviations: SGA,
small for gestational age; PNGR, postnatal growth retardation; m, months; y, years.
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have never been reported [33], it is conceivable a
different mechanism of pathogenicity, possibly
mediated by a cross-talk between MEST and ICR1.
According, recent advances sustain an interplay
among ICR1 and other iDMRs (our unpublished
data) and chromatin interactions between H19 and
portions of chromosome 7 [34]. MEST methylation
may also be part of an imprinting gene network
(IGN), involving the trans-acting functions of H19
lncRNA [35,36]. Further investigations are requested
to better elucidate this finding.
To explain MLID phenomenon, an underlying
genetic mechanism has been suggested, such as a
mutation in pleiotropic genes regulating DNAmethy-
lation. This hypothesis is intriguing and has been
corroborated by the identification of few genes (e.g.,
NLRP family genes), mutated in MLID patients.
Nevertheless, the real role of these genes has to be
fully elucidated, because mutated patients reported
in literature show clinical and epigenetic heterogene-
ity. These genes are generally considered to have a
‘maternal effect’ since they have a key role during the
early embryonic stages before full zygotic genome
activation. Maternally derived mutations of these
genes cause impaired or delayed preimplantation
development and have been associated to MLID
development through oocyte-stored transcripts [37].
Nevertheless, our data do not sustain this hypothesis,
since the paternally-derived NLRP2 mutation could
impair methylation, suggesting a function of NLRP2
occurring after embryonic-genome activation rather
than via oocyte-stored transcripts.
Our hypothesis, based on in silico modeling and
literature data of NLR protein family in the inflam-
masome response [30], is that mutNLRP2 remains in
an open conformation, leading to inappropriate
LOM at iDMRs. Although intriguing, this suggestion
is speculative in relation to NLRP2 embryonic epige-
netic function. Alternatively, mutNLRP2 may act as
dominant negative through oligomerization/seques-
tration of wtNLRP2 proteins. Moreover, all other
described NLRP2 mutations associated with MLID
in BWS/SRS patients [8,21] affect the NOD domain,
that delineates as a possible mutational hotspot with
a deleterious effect on methylation regulation.
The ZFP42 variant, identified in patient SRS-4,
although annotated as a polymorphism, is very rare
in the general population and is predicted to be
pathogenic. In silico modeling suggested a reduced
binding specificity of mutZFP42 on target DNA and
consequently a diminished binding competition with
the antagonist YY1 [38]. Based on SRS-4 MLID
pattern and according to literature data, showing
that the ZFP42 knockout causes LOM at several
iDMRs not including H19 [39], we speculate that
that the loss of binding specificity of the mutZFP42
may lead to LOM at iDMRs not normally controlled
by this factor. According to the paternal derivation
of the ZFP42 variant, we can assume that the timing
of the methylation aberration would be post embryo-
nic genome activation, working in a dominant-nega-
tive fashion, and resulting in LOM mosaicism.
Overall, the absence ofMLID and phenotypic effect
in both carrier fathersmay be explained by incomplete
penetrance, as already reported forNLRP2 [21,37] and
ZFP57 mutations [40]. Defining and proving the
pathogenic effect of MLID-associated mutations is,
indeed, challenging, given the poorly established
mechanism of transmission and lack of information
about the roles of analyzed factors in methylation.
However, there is strong justification for reporting
these variants in order to understand whether they
are really pathogenetic or only confer higher suscept-
ibility to single or multiple methylation defects, likely
in conjunction with additional yet unidentified var-
iants in methylation factors.
Regarding epigenotype-phenotype correlations
in patients with BWS-MLID, we confirmed the
absence of MLID-specific or recurrent clinical
signs. Given the variability of affected iDMRs, no
significant associations between epimutations and
phenotypes could be identified. Nevertheless,
MLID should be always suspected in female
patients with nevus flammeus, macroglossia, outer
ears anomalies and abdominal wall defects.
It is intriguing that both patients with MLID-
SRS were clinically misdiagnosed as BWS: one SRS
patient showed only hemihyperplasia (reclassified
as hemihypoplasia after clinical re-evaluation and
in light of molecular results), while the other
exhibited BWS-associated clinical signs.
Conclusions
Overall, our data indicate that MLID is frequent in
BWS/SRS and restricted to maternal iDMRs.
While searching for genetic defects associated
with MLID, we identified two additional
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nucleotide variants mapping at functional sites of
NLRP2 and ZFP42 genes. By checking for the
pattern of inheritance, we found a paternal deriva-
tion, never reported for such mutations. This evi-
dence suggests yet unexplored functions of these
genes, or different mechanisms of pathogenicity
and underline the importance of father’s testing.
BWS-MLID patients do not show peculiar clinical
signs, although MLID appears more frequent in
females with a specific phenotypic pattern. All this
information should be considered for genetic
counseling.
Methods
Study population
The study population included 21 patients with
BWS and ICR1/ICR2 epimutations: five (BWS
1–5) were referred to our laboratory during preg-
nancy, after detection of omphalocele by ultra-
sound imaging, and 16 were postnatal cases
(BWS 6–21). Among these latter, 11 were clinically
diagnosed according to Weksberg classification
[1], while diagnosis was only suspected in the
remaining five. We also studied seven cases with
SRS (SRS 1–7) and ICR1 LOM: three of these cases
achieved the Netchine-Harbison criteria for clin-
ical diagnosis of SRS [2], while diagnosis was only
suspected in the remaining four.
All clinical features of BWS and SRS patients are
reported in Figures 4 and 5, respectively.
All cases were collected between 2011 and 2016.
Appropriate informed consent was obtained from
all parents. The study was approved by the Ethics
Committee of Fondazione IRCSS Ca’ Granda
Ospedale Maggiore Policlinico (no. 526/2015).
All cases included in the study had a primary
methylation defects at ICR1/ICR2, as confirmed by
molecular diagnosis by pyrosequencing [41–43].
Genomic imbalances or UPD were excluded by
SNP array (Supplementary materials and methods).
The parents of two cases (BWS-15 and SRS-4)
were investigated to define the inheritance of var-
iants detected by NGS. The mutation identified in
patient BWS-15 was also evaluated in the DNA
from amniotic fluid from a subsequent pregnancy
of the family.
DNA samples from 100 aged-matched healthy
controls were included in the study: i) to set up the
MassARRAY methylation panel and define the
normal interval of methylation for each locus (50
individuals), and ii) to calculate the frequency of
NGS-identified variants in the general population
(100 individuals). In addition, 20 DNAs from
amniotic fluid of healthy pregnancies were used
to define normal methylation ranges of iDMRs
included in the MassARRAY platform for the
analysis of pre-natal BWS cases.
DNA isolation and bisulfite conversion
Genomic DNA was extracted from the peripheral
blood and amniotic fluid of patients and controls
using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany). DNA samples (500–700 ng)
were bisulfite converted using the EZ Direct
DNA Methylation Kit (Zymo Research, Irvine,
CA). In prenatal cases, maternal DNA contamina-
tion was excluded by qfPCR.
Methylation analysis by MassARRAY
Methylation profile of 12 iDMRs frequently
involved in MLID in BWS/SRS [7,8,10,15] was
investigated by the MassARRAY methylation plat-
form (Agena Bioscience, Hamburg, Germany).
Details on the setting up and on protocol are
reported in Supplementary materials and methods.
The investigated iDMRs, their genomic positions,
specific primers, and CpG sites are described in
Supplementary Table S2, which also includes pri-
mers and CpGs investigated for BWS/SRS molecular
diagnosis by pyrosequencing. The MassARRAY
ICR1 assay comprises the four CpG sites analyzed
by pyrosequencing, while the MassARRAY ICR2
sequence maps downstream of the pyrosequencing
assay. Aberrant methylation of iDMR in patients
was defined when the observed methylation value
fell outside the methylation range defined in con-
trols (mean ± two standard deviations).
Next-generation sequencing (NGS)
A panel of 25 genes (Supplementary Table S1)
involved in methylation establishment/maintenance
was designed for targeted NGS using the Agilent
906 L. FONTANA ET AL.
SureDesign online tool (Agilent Technologies, Santa
Clara, CA). NGS was performed on DNA from
patients with BWS- and SRS-MLID, using the
Agilent HaloPlex Target Enrichment kit (Agilent
Technologies) and an Illumina MiSeq sequencer
withMiSeq Reagent Kit V2 (Illumina, CA). A detailed
description of NGS procedures is reported in
Supplementary materials and methods.
Prediction of pathogenicity and computational
modeling studies
The pathogenic effects of variants identified by
NGS were predicted using online tools reported
in Supplementary materials and methods.
The structure of NLRP2 NOD (nucleotide-bind-
ing and oligomerization domain) was obtained by
homology modeling using as template the crystal
structure of the NOD2 in the ADP-bound (PDB:
1irm). The effect of the mutation on the NOD
structure and function was assessed by performing
200 ns of molecular dynamics simulations of wt
and mutated models.
To gain insight into the contribution spectrum
of binding energy for ADP-wtNLRP2 and ADP-
mutNLRP2, the enthalpy contributions during the
last 15 ns of simulations were computed.
The unbound zinc finger motifs of the ZFP42
protein were modeled by homology using the crystal
structure of the transcriptional repressor protein
YY1-DNA complex (PDB: 1ubd) as template. The
impact of the amino acid substitution on protein
folding and on ability to bind DNA was assessed by
performing 30 ns of molecular dynamics using the
ff03 force filed. To maintain the tetrahedral struc-
tures of the zinc-binding site of the C2H2 coordina-
tion, the cationic dummy atom approach was used
instead of a simple non-bonded model. The con-
formational change of zinc finger motifs during
simulation was evaluated by cluster analysis deter-
mining the most representative structures from
molecular dynamic simulations.
Statistical analyses
T-tests were used to compare ICR1 and ICR2
methylation values determined by MassARRAY
and pyrosequencing. For (epi)genotype-
phenotype correlations, Fisher’s exact tests were
performed.
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